ReShape Lifesciences ( (RSLS) ) has released a notification of late filing.
ReShape Lifesciences Inc. has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The company cited the need for additional time to complete the compilation of financial statements and related disclosures as the primary reason for the delay. Despite this setback, ReShape Lifesciences anticipates filing the report within the 15-day extension period allowed by Rule 12b-25. The company does not expect any significant changes in its financial results compared to the previous fiscal year. ReShape Lifesciences is committed to maintaining compliance and transparency, with the notification signed by Chief Financial Officer Thomas Stankovich.
More about ReShape Lifesciences
YTD Price Performance: -92.11%
Average Trading Volume: 1,229,241
Technical Sentiment Signal: Buy
Current Market Cap: $1.19M
See more data about RSLS stock on TipRanks’ Stock Analysis page.